Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis

Liver International

Volumn 32, Issue 10, 2012, Pages 1585-1595

  Liu, Yanling ^a   Xu, Li ^a   Zeng, Qili ^a   Wang, Jingli ^a   Wang, Ming ^a   Xi, Dong ^a   Wang, Xiaojing ^a   Yang, Daofeng ^a   Luo, Xiaoping ^a   Ning, Qin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

C Jun N terminal kinase (JNK); Extracellular signal regulated kinase (ERK); FGL2; Hepatocellular carcinoma (HCC); Protease activated receptor (PAR)

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FIBRIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRIN; FIBRINOGEN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOPLASTIN;

EID: 84867100989     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02865.x     Document Type: Article

References (41)

1. Xue YH, Zhang XF, Dong QZ, et al. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology 2010; 52: 2012-22.
2. Kaufmann R, Rahn S, Pollrich K, et al. Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 2007; 211: 699-707.
3. Snyder KM, Kessler CM. The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost 2008; 34: 734-41.
4. Horowitz NA, Blevins EA, Miller WM. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood 2011; 118: 2889-95.
5. Marazzi S, Blum S, Hartmann R, et al. Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. J Immunol. 1998; 161: 138-47.
6. Ding Y, Liu K, Wang Y, et al. Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes. J Huazhong Univ Sci Technolog Med Sci. 2010; 30: 575-81.
7. Chan CW, Chan MW, Liu M, et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol. 2002; 168: 5170-7.
8. Yuwaraj S, Ding J, Liu M, Marsden PA, Levy GA. Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: A novel human procoagulant. Genomics 2001; 71: 330-8.
9. Levy GA, Liu M, Ding J, et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000; 156: 1217-25.
10. Ding JW, Ning Q, Liu MF, et al. Expression of the fgl2 and its protein product in tissues during murine hepatitis virus strain-3 infection. Adv Exp Med Biol 1998; 440: 609-618.
11. Ning Q, Sun Y, Han M, et al. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol. 2005; 174: 7403-11.
12. Zhu CL, Yan WM, Zhu F, et al. Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J Gastroenterol 2005; 11: 6936-40.
13. Ghanekar A, Mendicino M, Liu H, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol. 2004; 172: 5693-701.
14. Clark DA, Foerster K, Fung L, et al. The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. Mol Hum Reprod 2004; 10: 99-108.
15. Liu M, Mendicino M, Ning Q, et al. Cytokine-induced hepatic apoptosis is dependent on FGL2/fibroleukin: The role of Sp1/Sp3 and STAT1/PU.1 composite cis elements. J Immunol. 2006; 176: 7028-38.
16. Su K, Chen F, Yan WM, et al. Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. World J Gastroenterol 2008; 14: 5980-5989.
17. Marsden PA, Ning Q, Fung LS, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest. 2003; 112: 58-66.
18. Jankovic R, Radulovic S, Brankovic-Magic M. siRNA and miRNA for the treatment of cancer. J BUON. 2009; 14(Suppl 1): S43-9.
19. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
20. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and cancer. Pharmacol Rev 2008; 60: 261-310.
21. Orton RJ, Sturm OE, Vyshemirsky V, et al. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J 2005; 392: 249-61.
22. Sun CK, Ng KT, Lim ZX, et al. Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS ONE 2011; 6: e18878.
23. Cullen BR. Induction of stable RNA interference in mammalian cells. Gene Ther 2006; 13: 503-8.
24. Bieker R, Kessler T, Schwoppe C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: Experimental results and first-in-man experience. Blood 2009; 113: 5019-27.
25. Sun HC, Li XM, Xue Q, et al. Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice. World J Gastroenterol 1999; 5: 116-118.
26. Schwartz S, George J, Ben-Shoshan J, et al. Drug modification of angiogenesis in a rat cornea model. Invest Ophthalmol Vis Sci 2008; 49: 250-4.
27. Huang X, Bai X, Cao Y, et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010; 207: 505-20.
28. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427-1431
29. Schubert R, Geiger H, Zielen S, Baer PC. Simultaneous detection of ERK-, p38-, and JNK-MAPK phosphorylation in human adipose-derived stem cells using the Cytometric Bead Array technology. J Immunol Methods 2009; 350: 200-4.
30. Elste AP, Petersen I. Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. J Mol Histol 2010; 41: 89-99.
31. Disse J, Petersen HH, Larsen KS, et al. The Endothelial Protein C Receptor Supports Tissue Factor Ternary Coagulation Initiation Complex Signaling through Protease-activated Receptors. J Biol Chem 2011; 286: 5756-67.
32. Martorell L, Martínez-González J, Rodríguez C, et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 2008; 99: 305-15.
33. Ishihara H, Connolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-506.
34. Wang H, Ubl JJ, Stricker R, Reiser G. Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. Am J Physiol Cell Physiol 2002; 283: C1351-64.
35. Zigler M, Kamiya T, Brantley EC, Villares GJ, Bar-Eli M. PAR-1 and Thrombin: The Ties That Bind the Microenvironment to Melanoma Metastasis. Cancer Res 2011; 71: 6561-6.
36. Kristin K. Fino, Rosalyn B. Irby, Jill P. Smith. Gastrin signaling and Par-4 in pancreatic cancer. Cancer Res, 2011; 71: 2891
37. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
38. Li A, Dubey S, Varney ML, Dave BJ. Singh RK.IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003; 170: 3369-76.
39. Caja L, Sancho P, Bertran E, et al. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res 2009; 69: 7595-602.
40. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med. 2009; 7: 41.
41. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.